Bullous pemphigoid carries a significantly elevated risk of death compared to the general population, though the disease itself is rarely the direct killer. Across multiple large studies, people with BP face roughly two to four times the mortality risk of age-matched peers, with much of that excess mortality driven by infections, cardiovascular events, and complications of treatment rather than the blisters themselves. The picture is more nuanced than a simple yes-or-no answer, because outcomes vary enormously depending on a patient’s age, overall health, and how the disease is managed.
Mortality Rates Vary Widely, but the Trend Is Clear
Pinning down a single mortality rate for BP is difficult because studies from different countries and time periods report different numbers. A large Italian retrospective study found one-year mortality of about 3%, rising to roughly 27% at five years and 52% at ten years.1PubMed. Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study A Swedish nationwide study of nearly 5,800 patients reported a much higher one-year mortality of about 21%, climbing to 80% at ten years.2PubMed Central. Increased Mortality in Patients with Bullous Pemphigoid: A Nationwide Population-based Cohort Study of 5,738 Patients in Sweden A UK population-based study reported one-year mortality around 19%.3PubMed Central. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study
These differences reflect real variation in patient populations, healthcare systems, and diagnostic criteria. The Italian cohort likely captured milder cases, which pushes early mortality down. The Swedish and UK data drew from national registries and probably included a broader severity spectrum. What every study agrees on is that BP patients die at rates well above what would be expected for their age. A systematic review and meta-analysis pooling data from multiple countries calculated a standardized mortality ratio of about 3.6, meaning BP patients die at roughly three and a half times the rate of age-matched peers.4PubMed. Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios A separate Dutch-led meta-analysis found a similar figure of about 3.4-fold increased risk.5PubMed. Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis
It is worth remembering that BP overwhelmingly affects older adults. The average age at diagnosis is typically in the late 70s or 80s. Some of the high long-term mortality reflects the natural mortality of an elderly population, not just the disease. But even after adjusting for age and sex, the excess risk persists.
What Patients Actually Die From
The blisters of BP are painful and debilitating, but they are not what kills people. The leading cause of death in BP patients is infection. Open skin wounds from ruptured blisters create entry points for bacteria, and the immunosuppressive drugs used to control the disease further compromise the body’s defenses. In one French study of patients who died within six months of diagnosis, sepsis was the cause of death in about half the cases where the cause was known, with pneumonia accounting for a large share of those infections.6JAMA Dermatology. High Risk of Death in Elderly Patients With Extensive Bullous Pemphigoid Cardiovascular disease was the second most common cause. A population-based study using death certificate data confirmed that infections, and sepsis in particular, appear on death certificates more frequently for BP patients than for matched controls.7International Journal of Dermatology. Specific Causes of Death in Patients with Bullous Pemphigoid as Measured by Death Certificate Data
The infection risk is not abstract. Among hospitalized BP patients in one study, bacterial skin infections were found in 40% of patients, with Staphylococcus aureus accounting for about three-quarters of those infections.8PubMed. Bacterial Skin Infections in Hospitalized Patients with Bullous Pemphigoid These are not minor skin infections but potential gateways to bloodstream infections in frail, elderly patients who may already have other health conditions.
Blood Clots as an Overlooked Complication
One complication that often surprises patients and even some clinicians is the elevated risk of venous thromboembolism, meaning deep vein thrombosis and pulmonary embolism. The systemic inflammation of BP, combined with the reduced mobility that comes with painful skin disease in elderly patients, creates a perfect storm for clot formation. A large nationwide cohort study with an accompanying meta-analysis of eight studies found that BP patients face roughly double the risk of blood clots compared to the general population.9PubMed Central. Risk of Incident Venous Thromboembolism Among Patients With Bullous Pemphigoid or Pemphigus Vulgaris: A Nationwide Cohort Study With Meta-Analysis
The risk is not constant throughout the disease course. During active flares, the danger spikes dramatically. One dedicated study found a roughly 15-fold increase in clot risk during the acute phase of BP, dropping back toward baseline during remission.10PubMed. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP study A JAMA Dermatology study using propensity-score matching confirmed a roughly twofold increased risk of clots even after accounting for 60 different risk factors and severity markers.11PubMed Central. Venous Thromboembolism in Patients With Bullous Pemphigoid Researchers have recommended that hospitalized or immobilized BP patients in particular be evaluated for preventive measures against clots.
Treatment Itself Can Be Dangerous
Here is where the story gets complicated for patients trying to weigh their options. The traditional mainstay of BP treatment has been systemic corticosteroids like prednisone, which suppress the overactive immune response causing the blisters. But these drugs carry serious side effects in the very population most affected by BP: elderly patients already at risk for infections, osteoporosis, diabetes, and cardiovascular events.
A landmark trial published in the New England Journal of Medicine compared oral prednisone to potent topical corticosteroids (applied directly to the skin) in patients with extensive BP. The results were striking. One-year survival was 76% in the topical group compared to 58% in the oral prednisone group. Severe complications hit 54% of those on oral steroids versus 29% of those on topical treatment.12PubMed. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid That is a large gap. A more recent analysis in the British Journal of Dermatology confirmed this pattern, finding that US patients treated with any dose of systemic corticosteroids had a roughly 43% higher risk of death compared to those treated with topical clobetasol. The systemic steroid group also faced higher rates of major cardiovascular events and infections.13British Journal of Dermatology. Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids
This does not mean oral steroids are never appropriate. Some patients have disease too severe or widespread for topical treatment alone, and newer combination approaches aim to minimize steroid exposure. But for patients and families trying to understand why BP is so dangerous, the treatment itself is a significant part of the answer.
Who Faces the Highest Risk
Not all BP patients face the same prognosis. Two factors stand out as the strongest independent predictors of death: age at diagnosis and functional status. A prospective French study found that patients over 83 years old had about 2.3 times the risk of death compared to younger patients, and bedridden patients had a fourfold increase. The combination was devastating: bedridden patients over 83 faced more than nine times the mortality risk of younger, more mobile patients.14JAMA Dermatology. Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study
Neurological conditions also play a role. BP has a well-documented association with neurodegenerative diseases. In one Central European study, about 28% of BP patients had a neurodegenerative condition, including stroke, Parkinson’s disease, and dementia.15PubMed Central. Bullous pemphigoid and neurodegenerative diseases: a study in a setting of a Central European university dermatology department The death certificate study mentioned earlier found that dementia appeared more frequently as a contributing cause of death in BP patients than in controls.7International Journal of Dermatology. Specific Causes of Death in Patients with Bullous Pemphigoid as Measured by Death Certificate Data This connection likely reflects both a shared biological link (the BP180 protein targeted by the autoimmune attack is also found in brain tissue) and the practical reality that patients with dementia are harder to treat, less able to report symptoms, and more vulnerable to complications.
Disease severity matters too, though quantifying it is less straightforward. Levels of antibodies against BP180, one of the proteins attacked in BP, track moderately well with disease activity scores at diagnosis and during follow-up.16PubMed Central. Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis These antibody levels also help predict who will relapse after treatment ends, which we will return to shortly.
Living With BP Beyond Survival
Focusing solely on whether BP kills misses a large part of the story. For patients who survive, the disease imposes a heavy daily burden. Itching is the symptom patients report as most distressing, often more than the blisters themselves. A prospective study found that 85% of BP patients experienced daily itching, with an average intensity of about 5 out of 10. Most patients also reported tingling and burning sensations. The impact on quality of life was substantial, with itch scores indicating poor tolerance across the board.17PubMed Central. Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study
The psychological toll deserves its own attention. A qualitative study interviewing BP patients found a wide range of emotional impacts during disease flares, including anxiety, depression, stress, embarrassment, and a particular fear of the disease returning. Five of six salient symptoms and four of thirteen salient quality-of-life impacts were rated above 7.5 out of 10 in disturbance, indicating that BP is a “highly burdensome disease” in patients’ own words.18PubMed Central. Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts Sleep disturbance, changes in clothing choices to hide lesions, and limitations on daily activities were all common. The relapsing nature of BP amplifies these fears; even during remission, many patients live with ongoing anxiety about when the next flare will come.
About a third of patients develop mucosal involvement, with erosions most frequently appearing on the soft palate and inner cheeks.19Our Dermatology Online. Mucosal involvement in bullous pemphigoid in Northeast Morocco Mucosal lesions tend to signal more severe disease overall, correlating with higher disease activity scores.20PubMed Central. Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody Oral erosions make eating painful, which can contribute to malnutrition in patients who are already frail.
The Cancer Question
One of the most persistent concerns among newly diagnosed BP patients is whether the disease signals an underlying cancer. Case reports going back decades have described individual patients in whom BP and cancer appeared together, fueling speculation about a link. But the best available evidence says the association is largely a myth. A population-based cohort study found the number of cancers diagnosed after BP was almost exactly what would be expected by chance, with a standardized incidence ratio of 0.97.21JAMA Dermatology. Association of Bullous Pemphigoid and Malignant Neoplasms A systematic review and meta-analysis similarly found no association between BP and overall cancer across multiple study designs, though a pooled analysis of cross-sectional studies did find a signal for blood cancers specifically.22PubMed. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis
The bottom line for patients: a BP diagnosis does not mean you need an aggressive cancer workup beyond standard age-appropriate screening. The occasional case reports of BP resolving after cancer treatment likely reflect coincidence or, at most, very rare paraneoplastic cases that are not representative of the broader BP population.23PubMed Central. Association of bullous pemphigoid with malignancy: a myth or reality?
Relapse After Remission
Even patients who achieve complete remission with treatment face a meaningful risk of relapse. BP is a chronic autoimmune condition, and the immune memory that drives it does not always disappear when the blisters clear. Several factors at diagnosis can help predict who is most likely to relapse.
The strongest predictor identified in prospective research is the level of anti-BP180 antibodies at the start of treatment. A multicenter prospective study found that patients whose antibody titers exceeded a certain threshold at diagnosis had a 91% chance of relapsing within the year after stopping treatment.24JAMA Dermatology. Risk Factors for Relapse in Patients With Bullous Pemphigoid in Clinical Remission Antibody levels tracked disease activity during treatment as well, falling when the disease was controlled and rising before clinical relapse.25Archives of Dermatology. Serum Levels of Autoantibodies to BP180 Correlate With Disease Activity in Patients With Bullous Pemphigoid
Other factors linked to relapse include older age, the presence of neurological disorders, and certain nutritional markers. A retrospective study of 205 patients found that low prealbumin levels (a marker of nutritional status) and certain immunofluorescence patterns at diagnosis independently predicted future relapses.26International Immunopharmacology. Risk factors predisposing relapse of bullous pemphigoid at initial diagnosis: A retrospective cohort study of 205 patients The practical takeaway is that BP management does not end when the blisters clear. Ongoing monitoring, gradual medication tapering, and periodic antibody testing can help catch relapses early.
Newer Therapies and Whether They Change the Outlook
The recognition that systemic steroids contribute to BP mortality has driven interest in alternative treatments. Several biologic drugs originally developed for other conditions have shown promise in BP, though the evidence base is still relatively thin and largely built on case series rather than large randomized trials.
A systematic review found that rituximab, omalizumab, and dupilumab each achieved complete remission in roughly two-thirds of treated patients. Rituximab had the highest complete remission rate at about 71% but also the highest death rate during treatment at 9%, with infections being the most common serious side effect. Omalizumab and dupilumab showed lower recurrence rates and fewer adverse events, with dupilumab reporting no serious adverse events in the reviewed cases, though the numbers were small.27PubMed Central. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review Dupilumab in particular has drawn interest because it may allow lower steroid doses while maintaining disease control.28JAMA Dermatology. Evaluation of Dupilumab in Patients With Bullous Pemphigoid
Combination approaches are also being explored. In one comparative cohort, patients receiving rituximab combined with omalizumab achieved disease control in about 15 days versus nearly 68 days for rituximab alone, with lower total steroid exposure.29Dermatologic Therapy. Dual‐Biologic Therapy in Refractory Bullous Pemphigoid: A Focused Review of Rituximab–Omalizumab and Omalizumab–Dupilumab If faster control and less steroid use translates into fewer infections and cardiovascular events, these newer regimens could meaningfully improve survival. But for now, that link remains theoretical; no large trial has directly shown that biologic-based treatment lowers BP mortality.
Wound Care and the Underestimated Practical Side
Something that rarely gets attention in discussions about BP mortality and complications is the role of basic wound care. Patients with extensive blistering face the same challenges as burn patients: large areas of denuded skin that are vulnerable to fluid loss, bacterial colonization, and pain. Keeping wounds clean and moist while preventing secondary infection is a daily reality for many BP patients and their caregivers.
One recent trial tested ozone-infused liquid dressings as a supplement to standard wound care in BP patients and found that the group receiving the additional wound treatment had a significantly higher complete healing rate, reaching about 62% compared to 38% with standard care alone. Pain scores dropped by half within three days, and bacterial culture positivity declined faster in the treated group.30PubMed Central. Evaluating the therapeutic efficacy of ozone liquid dressing in healing wounds associated with bullous pemphigoid While this is a single trial and ozone dressings are not widely available, it underscores a broader point: meticulous wound care is not a minor adjunct to BP treatment. It directly affects infection risk, pain, and healing speed, all of which feed into the complications that drive mortality.
For patients and caregivers managing BP at home, attention to wound hygiene, use of non-adherent dressings, and prompt medical attention for signs of infection (increasing redness, warmth, pus, or fever) are among the most practical things that can influence outcomes. These conversations often get overshadowed by discussions about which drug to use, but for an elderly patient with fragile skin and limited mobility, daily wound management may matter as much as the medication choices.
A Disease Getting More Common
BP incidence appears to be rising in many countries, though the reasons are debated. A long-running study in Olmsted County, Minnesota, documented a significant increase in BP incidence over six decades.31PubMed Central. Incidence and Mortality Rates of Bullous Pemphigoid in Olmsted County, Minnesota, Over 6 Decades Globally, the average incidence sits at about 2 cases per 100,000 people per year, with the UK reporting the highest figures at roughly 7.6 per 100,000.32PubMed Central. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid Part of this increase may reflect better recognition and diagnosis rather than a true rise in disease frequency, and the aging of populations worldwide is almost certainly a factor, given that BP risk climbs steeply with age. Some researchers have also pointed to medications like DPP-4 inhibitors (a class of diabetes drug) as a potential contributor, since these drugs have been associated with triggering BP in susceptible individuals.
Whatever the cause, a growing BP population means more clinicians will encounter the disease and more families will need to understand its risks. The reassuring news is that awareness of the dangers of systemic steroids has improved, topical steroid protocols are more widely adopted, and newer biologic options are expanding the treatment toolkit. Whether these trends will bend the mortality curve downward remains to be seen, but the trajectory of care is moving in a direction that should, over time, make BP less lethal than the older studies suggest.